Vanda’s Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review
Hand-out
Press Releases
Vanda Pharmaceuticals Inc.  
January 8, 2025

Vanda’s Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

WASHINGTON, Jan. 8, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) letter to FDA Commissioner highlights faulty gastroparesis NDA review.

avatar profile Olean Times Herald

Olean Times Herald


Local & Social